

# PulseCath iVAC 2L Post-Market Surveillance Form

Operator:  Date:  Serial n:

Hospital:  NYHA (Heart failure classification)  I  II  III  IV

Age:  Gender:  Male  Female

Weight (Kg):  Height (cm):  Indication:  ACUTE CORONARY SYNDR.  EMERGENT  STABLE ANGINA  URGENT  OTHER:   ELECTIVE

SYNTAX I:

STS mort.:

EF (%):

## Antecedents – mark if present

- Diabetes II  Periph. Artery Disease  Venous thrombosis  
 Hypertension  Ischemic Stroke  Myoc. Infarction  
 Kidney Failure  Hemorrhagic Stroke  Previous PCI  
 Smoking /COPD  Atrial Fibrillation  Previous CABG  
 Dyslipidemia  Ventricular Arrhythmias  Surgery Refusal  
 Chronic Anticoag.  Hemodialysis  Cancer

VALVE	LESION		SEVERITY		
	REGURG	STENOSIS	MILD	MOD	SEVERE
AORTIC	REGURG	STENOSIS	MILD	MOD	SEVERE
MITRAL	REGURG	STENOSIS	MILD	MOD	SEVERE
TRICUSPID	REGURG	STENOSIS	MILD	MOD	SEVERE
PULMONIC	REGURG	STENOSIS	MILD	MOD	SEVERE

## Treatment – indicate lesion severity and mark “STENT” if treated

- 50%  90%  CTO  STENT LM (Left Main)    
  50%  90%  CTO  STENT LCx (Circumflex)    
  50%  90%  CTO  STENT RCA (Right Coronary)  
 50%  90%  CTO  STENT LAD (Left Ant. Desc.)    
  50%  90%  CTO  STENT 1OM (1<sup>st</sup> Obtuse Marginal)    
  50%  90%  CTO  STENT RPD (Post. Desc.)  
 50%  90%  CTO  STENT 1DG (1<sup>st</sup> Diagonal)    
  50%  90%  CTO  STENT 2OM (2<sup>nd</sup> Obtuse Marginal)    
  50%  90%  CTO  STENT PL (Posterolateral)  
 50%  90%  CTO  STENT 2DG (2<sup>nd</sup> Diagonal)    
  50%  90%  CTO  STENT LPD (Left Posterior Desc.)    
  50%  90%  CTO  STENT Bypass Graft  
 50%  90%  CTO  STENT SB (Septal Branch)    
  50%  90%  CTO  STENT RI (Intermediate Branch)    
  50%  90%  CTO  STENT Other:

N. of lesions treated:  N. of stents deployed:  Highest ACT:   UNPROTECTED LEFT MAIN  LAST PATENT VESSEL  IVUS  
 3-VESSEL DISEASE  ANTEGR. ART. BYPASS  ROTABLATION

iVAC start:  iVAC end:  Max. iVAC2L flow (L/min):  Access Site:  Sheath (name/size/serial n):

Assist Mode:  1:1 synch  1:3 synch  Internal  
 Vasc. Closure:  MANTA  PROGLIDE  SURGICAL  
 Total IV fluids (mL):  Total contrast (mL):  Hospital Admission:  Hospital Discharge:

## Intraprocedural Events & Clinical Outcomes – mark if present

- Death (intraprocedural)  Blood transfusion (red cells)  No Major Adverse Events at 30 days  
 Hypotension (10 min with MAP < 60)  REASON: BLEEDING / SEVERE ANEMIA HEMOLYSIS   
 Shock (30 min with SBP < 90)  Hemolysis (clin. Significant)  
 Cardiac Massage (CPR)  Failure to implant  
 Defibrillation/cardioversion  Other support used  
 Atropine/adrenaline use  WHICH:   
 Noradrenaline use  Premature removal of iVAC2L  
 Dobutamine use  Lesion to the aortic valve (TTE)  
 Intubation (if emergent)  Angiographic failure  
 Dislocation of iVAC2L  Intrapr. Infusion weaning (dobutamine/noradrenaline/dopamine)
- |  | PRE DISCHARGE | < 30 DAYS | < 90 DAYS | < 1 YEAR |                         |
|--|---------------|-----------|-----------|----------|-------------------------|
| <input type="checkbox"/> Major Adverse Events at 30 days             |               |           |           |          |                         |
| <input type="checkbox"/> Major Adverse events (mark “x” if occurred) |               |           |           |          |                         |
|  |               |           |           |          | Cerebrovasc. event      |
|  |               |           |           |          | Acute MI                |
|  |               |           |           |          | Acute Kidney Injury     |
|  |               |           |           |          | Cardiac/vasc. operation |
|  |               |           |           |          | Major bleeding          |
|  |               |           |           |          | Death                   |
|  |               |           |           |          | Emergent Revasc.        |

	HEART RATE	BLOOD PRESSURE	PULMONARY PRESSURE	CARDIAC OUTPUT	mPCWP	SpO2 (%)	SpO2 (%) (iVAC2L LEG / CONTRALATERAL LEG)
PRE-SUPPORT							
DURING SUPPORT (min 10 min)							
POST-REMOVAL							

We would greatly appreciate if you could inform PulseCath of any adverse events detected post PCI and post discharge. Thank you for contributing to our PMS registry! Please send a digitized copy of this form to:

[OREN@PULSECATH.COM](mailto:OREN@PULSECATH.COM)